

Giada Zurlo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5161045/publications.pdf>

Version: 2024-02-01

9
papers

338
citations

1163117

8
h-index

1474206

9
g-index

11
all docs

11
docs citations

11
times ranked

533
citing authors

#	ARTICLE	IF	CITATIONS
1	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. <i>Science</i> , 2018, 361, 290-295.	12.6	134
2	New Insights into Protein Hydroxylation and Its Important Role in Human Diseases. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1866, 208-220.	7.4	49
3	Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss. <i>Molecular Cell</i> , 2020, 77, 1294-1306.e5.	9.7	41
4	Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 1706-1721.	9.4	35
5	Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer. <i>Nature Communications</i> , 2019, 10, 5177.	12.8	27
6	ZHX2 promotes HIF1 α oncogenic signaling in triple-negative breast cancer. <i>ELife</i> , 2021, 10, .	6.0	21
7	Egln2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor. <i>Oncotarget</i> , 2017, 8, 6787-6795.	1.8	16
8	The Roles of Cullin-2 E3 Ubiquitin Ligase Complex in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1217, 173-186.	1.6	12
9	Adenylosuccinate lyase hydroxylation contributes to triple negative breast cancer via the activation of cMYC. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1707045.	0.7	3